Novo Nordisk Surges with Wegovy Success Amid Eli Lilly Rivalry

Novo Nordisk surpassed first-quarter profit expectations with strong sales of its new Wegovy weight-loss pill. Adjusted operating profit reached 32.86 billion Danish crowns. The company is adjusting its full-year outlook, standing firm against U.S. competitor Eli Lilly in the obesity drug market.

In a notable financial performance, Novo Nordisk exceeded first-quarter profit projections, driven by robust sales of its recently launched Wegovy weight-loss pill. The Danish pharmaceutical giant reported an adjusted operating profit of 32.86 billion Danish crowns, outshining the anticipated 28.74 billion.

This performance offers Novo an opportunity to regain momentum against its rival Eli Lilly, amidst a competitive landscape in the obesity drug market. The company adjusted its forecast, expecting a decline in adjusted sales and profit between 4% and 12%, an improvement over prior estimates.

Novo's share price has struggled over the past year, losing significant market value. However, with the early success of Wegovy and strategic adjustments under new leadership, the company aims to navigate intensifying competition following Eli Lilly's FDA approval for its rival drug, Foundayo.